New Phase III data shows greater treatment response with GSK’s Benlysta® (belimumab) vs placebo in patients with highly active SLE

Source: GSK Press Release

GSK today announced data at the Annual European Congress of Rheumatology (EULAR 2016) showing that patients with highly active systemic lupus erythematosus (SLE) experienced a significantly greater response to treatment with Benlysta (belimumab) 200mg administered via subcutaneous injection (injection under the skin) plus standard of care, compared to placebo plus standard of care. High SLE disease activity is associated with flares and a range of effects on organs.